P1302 THE OPTIMAL IMMUNOSUPPRESSION REGIMEN FOR DELAYING FIBROSIS PROGRESSION IN HCV AFTER LIVER TRANSPLANTATION

of 73% (56/77). No deaths occurred; no clinically meaningful differences were observed in frequencies of serious adverse events (AEs), AEs leading to discontinuation, or grade 3/4 AST/ALT elevations in patients with or without cirrhosis. Conclusions: All-oral DCV+ASV treatment exhibited similarly high SVR rates and no clinically relevant differences in safety/tolerability in cirrhotic and non-cirrhotic patients with HCV genotype 1b infection.